Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

9. listopadu 2026 aktualizováno: ViiV Healthcare

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

75

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 60 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).

  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
  • Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive Hepatitis C antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cohort 1: VH4011499 + Ritonavir

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

VH4011499 is administered to the participants based on the protocol schedule.

Ritonavir is administered to the participants based on the protocol schedule.

Experimentální: Cohort 2: VH4011499 + Efavirenz

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

VH4011499 is administered to the participants based on the protocol schedule.

Efavirenz is administered to the participants based on the protocol schedule.

Experimentální: Cohort 3: VH4011499 + Carbamazepine

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

VH4011499 is administered to the participants based on the protocol schedule.

Carbamazepine is administered to the participants based on the protocol schedule.

Experimentální: Cohort 4: VH4011499 + Metformin + Digoxin

Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Metformin is administered to the participants based on the protocol schedule.

Digoxin is administered to the participants based on the protocol schedule.

Experimentální: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Rosuvastatin is administered to the participants based on the protocol schedule.

Pitavastatin is administered to the participants based on the protocol schedule.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
Cmax of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Cmax of Metformin when administered alone
Časové okno: Day 1
Day 1
Cmax of Metformin when co-administered with VH4011499
Časové okno: Day 16
Day 16
AUC(0-t) of Metformin when administered alone
Časové okno: Day 1
Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
Časové okno: Day 16
Day 16
AUC(0-inf) of Metformin when administered alone
Časové okno: Day 1
Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
Časové okno: Day 16
Day 16
Cmax of Digoxin when administered alone
Časové okno: Day 1
Day 1
Cmax of Digoxin when co-administered with VH4011499
Časové okno: Day 16
Day 16
AUC(0-t) of Digoxin when administered alone
Časové okno: Day 1
Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
Časové okno: Day 16
Day 16
AUC(0-inf) of Digoxin when administered alone
Časové okno: Day 1
Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
Časové okno: Day 16
Day 16
Cmax of Rosuvastatin when administered alone
Časové okno: Day 5
Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
Časové okno: Day 22
Day 22
AUC(0-t) of Rosuvastatin when administered alone
Časové okno: Day 5
Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Časové okno: Day 22
Day 22
AUC(0-inf) of Rosuvastatin when administered alone
Časové okno: Day 5
Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Časové okno: Day 22
Day 22
Cmax of Pitavastatin when administered alone
Časové okno: Day 1
Day 1
Cmax of Pitavastatin when co-administered with VH4011499
Časové okno: Day 17
Day 17
AUC(0-t) of Pitavastatin when administered alone
Časové okno: Day 1
Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Časové okno: Day 17
Day 17
AUC(0-inf) of Pitavastatin when administered alone
Časové okno: Day 1
Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Časové okno: Day 17
Day 17

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of participants with adverse events (AEs), overall and by grade.
Časové okno: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
Časové okno: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Časové okno: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Časové okno: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
Tmax of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
CL/F of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Časové okno: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
Časové okno: Day 26
Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
Časové okno: Day 37
Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
Časové okno: Day 41
Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Časové okno: Day 16
Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Časové okno: Day 16
Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Časové okno: Day 16
Day 16
Cmax of Ritonavir when co-administered with VH4011499
Časové okno: Day 26
Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
Časové okno: Day 26
Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Časové okno: Day 26
Day 26
Cmax of Efavirenz when co-administered with VH4011499
Časové okno: Day 37
Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
Časové okno: Day 37
Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Časové okno: Day 37
Day 37
Cmax of Carbamazepine when co-administered with VH4011499
Časové okno: Day 41
Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Časové okno: Day 41
Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Časové okno: Day 41
Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
Časové okno: Day 22
Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Časové okno: Day 22
Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Časové okno: Day 22
Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
Časové okno: Day 17
Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Časové okno: Day 17
Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Časové okno: Day 17
Day 17

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

16. listopadu 2026

Primární dokončení (Odhadovaný)

12. března 2027

Dokončení studie (Odhadovaný)

12. března 2027

Termíny zápisu do studia

První předloženo

9. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

9. listopadu 2026

První zveřejněno (Aktuální)

16. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 309014

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

Časový rámec sdílení IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Kritéria přístupu pro sdílení IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF
  • CSR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .